Pulmonary embolism (PE) continues to challenge clinicians with its complex presentation and potential for rapid deterioration. As the third leading cause of cardiovascular mortality in the U.S.

Background: Acute pulmonary embolism (PE) is a critical disease and often leads to high mortality and morbidity. Growing studies have identified the diagnosis and treatment of PE, but the cognitive ...

Pulmonary embolism (PE), a type of blood clot in the lungs, sends more than half a million people to U.S. hospitals each year - and kills about one in five high-risk patients, according to the ...

Acute pulmonary embolism (APE), a critical complication following permanent pacemaker implantation, presents profound therapeutic challenges when occurring during the early postoperative phase. We ...

This summer I wrote an article about my experience with a postsurgical pulmonary embolism, hoping that sharing my story would help others take their own medical warning signs seriously. Hundreds of ...

Diego Ayo, M.D., a board-certified and fellowship-trained vascular surgeon at AdventHealth Pepin Heart Institute. A pulmonary embolism is a blood clot that limits or blocks blood flow to your lungs — ...

Imperative Care announced today that the FDA granted 510(k) clearance for its Symphony thrombectomy system to treat pulmonary embolism (PE). The clearance expands the use of Symphony, which previously ...

This Collection supports and amplifies research related to SDG 3: Good Health & Well-Being. This Collection invites original research considering diagnostic criteria, prognosis evaluation, and ...

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Use AARP’s interactive scam-tracking map to easily search for ...

Acute pulmonary embolism (PE) remains a diagnostic and therapeutic challenge, with an estimated 60,000-100,000 deaths each year in the United States. 1 Although the management of high-risk PE ...

According to Nova One Advisor, the global pulmonary embolism market size is calculated at USD 2.15 billion in 2024, grows to USD 2.33 billion in 2025, and is projected to hit around USD 4.78 billion ...

Penumbra (NYSE:PEN) announced today that it completed enrollment in the STORM-PE trial of its Lightning Flash system. STORM-PE evaluates Lightning Flash computer-assisted vacuum thrombectomy (CAVT) ...